These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21527535)

  • 1. The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/glycoprotein IIbIIIa antagonist, exceeds that of the coadministered parent compounds.
    Hechler B; Freund M; Alame G; Leguay C; Gaertner S; Cazenave JP; Petitou M; Gachet C
    J Pharmacol Exp Ther; 2011 Aug; 338(2):412-20. PubMed ID: 21527535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EP217609, a neutralisable dual-action FIIa/FXa anticoagulant, with antithrombotic effects in arterial thrombosis.
    Alame G; Mangin PH; Freund M; Riehl N; Magnenat S; Petitou M; Hechler B; Gachet C
    Thromb Haemost; 2015 Feb; 113(2):385-95. PubMed ID: 25374268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In stent restenosis and thrombosis assessment after EP224283 injection in a rat model.
    Maurel B; Chai F; Maton M; Blanchemain N; Haulon S
    Atherosclerosis; 2013 Aug; 229(2):462-8. PubMed ID: 23880206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immobilisation of an anti-platelet adhesion and anti-thrombotic drug (EP224283) on polydopamine coated vascular stent promoting anti-thrombogenic properties.
    Bricout N; Chai F; Sobocinski J; Hertault A; Laure W; Ung A; Woisel P; Lyskawa J; Blanchemain N
    Mater Sci Eng C Mater Biol Appl; 2020 Aug; 113():110967. PubMed ID: 32487386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
    Moriguchi A; Maeda M; Mihara K; Aoki T; Matsuoka N; Mutoh S
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):75-86. PubMed ID: 15678114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
    Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA
    Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban.
    Umemura K; Kondo K; Ikeda Y; Nakashima M
    Thromb Haemost; 1997 Nov; 78(5):1381-4. PubMed ID: 9408023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute basilar artery thrombosis with a combination of systemic alteplase and tirofiban, a nonpeptide platelet glycoprotein IIb/IIIa inhibitor: report of four cases.
    Junghans U; Seitz RJ; Wittsack HJ; Aulich A; Siebler M
    Radiology; 2001 Dec; 221(3):795-801. PubMed ID: 11719681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study.
    Talreja D; Lubbe D; Orford JL; Lennon R; DiBattiste PM; Berger PB
    J Thromb Thrombolysis; 2004 Aug; 18(1):25-30. PubMed ID: 15744550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
    Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
    Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of SanOrg123781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel.
    Lorrain J; Lechaire I; Gauffeny C; Masson R; Roome N; Herault JP; O'Connor SE; Schaeffer P; Herbert JM
    J Pharmacol Exp Ther; 2004 Apr; 309(1):235-40. PubMed ID: 14718579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons.
    Rao AK; Sun L; Hiramatsu Y; Gorman JH; Edmunds LH
    Thromb Haemost; 1999 Jul; 82(1):140-4. PubMed ID: 10456468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation.
    Stoll P; Bassler N; Hagemeyer CE; Eisenhardt SU; Chen YC; Schmidt R; Schwarz M; Ahrens I; Katagiri Y; Pannen B; Bode C; Peter K
    Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1206-12. PubMed ID: 17322097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
    Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
    Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
    Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
    Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y₁₂ receptor and phosphodiesterase.
    Hu L; Fan Z; Du H; Ni R; Zhang S; Yin K; Ye J; Zhang Y; Wei X; Zhang X; Gross PL; Kunapuli SP; Ding Z
    Thromb Haemost; 2011 Dec; 106(6):1203-14. PubMed ID: 21946947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.